ADLM/AACC 2023
This study evaluates analytical performance of an early version of Harbinger’s cfDNA methylation–based MCED assay. High performance and high technical reproducibility results validate the assay’s ability to perform early-stage multi-cancer detection, where levels of circulating tumor DNA are low.
